Literature DB >> 34282158

Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities.

Eva Kriegova1, Regina Fillerova2, Jiri Minarik3, Jakub Savara2,4, Jirina Manakova2, Anna Petrackova2, Martin Dihel2, Jana Balcarkova3, Petra Krhovska3, Tomas Pika3, Petr Gajdos4, Marek Behalek4, Michal Vasinek4, Tomas Papajik3.   

Abstract

Extramedullary disease (EMM) represents a rare, aggressive and mostly resistant phenotype of multiple myeloma (MM). EMM is frequently associated with high-risk cytogenetics, but their complex genomic architecture is largely unexplored. We used whole-genome optical mapping (Saphyr, Bionano Genomics) to analyse the genomic architecture of CD138+ cells isolated from bone-marrow aspirates from an unselected cohort of newly diagnosed patients with EMM (n = 4) and intramedullary MM (n = 7). Large intrachromosomal rearrangements (> 5 Mbp) within chromosome 1 were detected in all EMM samples. These rearrangements, predominantly deletions with/without inversions, encompassed hundreds of genes and led to changes in the gene copy number on large regions of chromosome 1. Compared with intramedullary MM, EMM was characterised by more deletions (size range of 500 bp-50 kbp) and fewer interchromosomal translocations, and two EMM samples had copy number loss in the 17p13 region. Widespread genomic heterogeneity and novel aberrations in the high-risk IGH/IGK/IGL, 8q24 and 13q14 regions were detected in individual patients but were not specific to EMM/MM. Our pilot study revealed an association of chromosome 1 abnormalities in bone marrow myeloma cells with extramedullary progression. Optical mapping showed the potential for refining the complex genomic architecture in MM and its phenotypes.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34282158     DOI: 10.1038/s41598-021-93835-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  50 in total

1.  Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.

Authors:  Cindy Varga; Wanling Xie; Jacob Laubach; Irene M Ghobrial; Elizabeth K O'Donnell; Matthew Weinstock; Claudia Paba-Prada; Diane Warren; Michelle E Maglio; Robert Schlossman; Nikhil C Munshi; Noopur Raje; Edie Weller; Kenneth C Anderson; Constantine S Mitsiades; Paul G Richardson
Journal:  Br J Haematol       Date:  2015-06       Impact factor: 6.998

Review 2.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

3.  Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.

Authors:  Saad Z Usmani; Christoph Heuck; Alan Mitchell; Jackie Szymonifka; Bijay Nair; Antje Hoering; Yazan Alsayed; Sarah Waheed; Sajjad Haider; Alejandro Restrepo; Frits Van Rhee; John Crowley; Bart Barlogie
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 4.  Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.

Authors:  Joan Bladé; Carlos Fernández de Larrea; Laura Rosiñol; María Teresa Cibeira; Raquel Jiménez; Ray Powles
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

5.  Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.

Authors:  Jan B Egan; K Martin Kortuem; Ahmet Kurdoglu; Tyler Izatt; Jessica Aldrich; Rebecca Reiman; Lori Phillips; Angela Baker; Chang-Xin Shi; Jessica Schmidt; Winnie S Liang; David W Craig; John D Carpten; A Keith Stewart
Journal:  Br J Haematol       Date:  2013-03-11       Impact factor: 6.998

Review 6.  Extramedullary Disease in Multiple Myeloma.

Authors:  Megan H Jagosky; Saad Z Usmani
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

7.  Cytogenetics of extramedullary manifestations in multiple myeloma.

Authors:  Lisa Billecke; Eva M Murga Penas; Annette M May; Monika Engelhardt; Arnon Nagler; Merav Leiba; Ginette Schiby; Nicolaus Kröger; Jozef Zustin; Andreas Marx; Jakob Matschke; Markus Tiemann; Eray Goekkurt; Hans-Heinrich Heidtmann; Eik Vettorazzi; Judith Dierlamm; Carsten Bokemeyer; Georgia Schilling
Journal:  Br J Haematol       Date:  2013-02-01       Impact factor: 6.998

8.  Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance.

Authors:  Xiaoyan Qu; Lijuan Chen; Hairong Qiu; Hua Lu; Hanxin Wu; Hongxia Qiu; Peng Liu; Rui Guo; Jianyong Li
Journal:  Biomed Res Int       Date:  2015-04-23       Impact factor: 3.411

9.  Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.

Authors:  Ashley R Paquin; Shaji K Kumar; Francis K Buadi; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; David Dingli; Lisa Hwa; Amie Fonder; Miriam Hobbs; Suzanne R Hayman; Steven R Zeldenrust; John A Lust; Stephen J Russell; Nelson Leung; Prashant Kapoor; Ronald S Go; Yi Lin; Wilson I Gonsalves; Taxiarchis Kourelis; Rahma Warsame; Robert A Kyle; S Vincent Rajkumar
Journal:  Blood Cancer J       Date:  2018-12-11       Impact factor: 11.037

10.  Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses.

Authors:  S J de Haart; S M Willems; T Mutis; M J Koudijs; M T van Blokland; H M Lokhorst; R A de Weger; M C Minnema
Journal:  Blood Cancer J       Date:  2016-05-20       Impact factor: 11.037

View more
  3 in total

1.  Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL).

Authors:  Anna Puiggros; Silvia Ramos-Campoy; Joanna Kamaso; Mireia de la Rosa; Marta Salido; Carme Melero; María Rodríguez-Rivera; Sandrine Bougeon; Rosa Collado; Eva Gimeno; Rocío García-Serra; Sara Alonso; Marco Antonio Moro-García; María Dolores García-Malo; Xavier Calvo; Leonor Arenillas; Ana Ferrer; Tuomo Mantere; Alexander Hoischen; Jacqueline Schoumans; Blanca Espinet
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

2.  Optical genome mapping identifies clinically relevant genomic rearrangements in prostate cancer biopsy sample.

Authors:  Yeeun Shim; Jongsoo Lee; Jieun Seo; Cheol Keun Park; Saeam Shin; Hyunho Han; Seung-Tae Lee; Jong Rak Choi; Byung Ha Chung; Young Deuk Choi
Journal:  Cancer Cell Int       Date:  2022-10-08       Impact factor: 6.429

3.  Optical Genome Mapping in Routine Human Genetic Diagnostics-Its Advantages and Limitations.

Authors:  Paul Dremsek; Thomas Schwarz; Beatrix Weil; Alina Malashka; Franco Laccone; Jürgen Neesen
Journal:  Genes (Basel)       Date:  2021-12-08       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.